Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Abstract (English)

Among patients with HFrEF, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.